Cargando…

Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real‐world study

INTRODUCTION: The effectiveness and safety of immune checkpoint inhibitor (ICI) monotherapy in advanced upper tract urothelial carcinoma (UTUC) is less reported. METHODS: In total, 106 consecutive advanced UTUC patients receiving ICI monotherapy were collected from nine high volume centers. Clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Ruopeng, Chen, Zeyu, Hong, Daoping, Jiang, Shuai, Yuan, Yichu, Cai, Xingyun, Hu, Hailong, Fu, Changde, Huang, Zhiyang, Wang, Zhenyu, Zheng, Bing, Huang, Jian, Wang, Zaoyu, Bao, Yige, Cai, Ming, Guo, Jianming, Chen, Minfeng, Wei, Qiang, Huang, Jiwei, Xue, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225242/ https://www.ncbi.nlm.nih.gov/pubmed/36952461 http://dx.doi.org/10.1002/cam4.5796

Ejemplares similares

The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy
por: Huang, Jiwei, et al.
Publicado: (2022)

Clinical outcomes of immune checkpoint inhibitor plus nab-paclitaxel in metastatic upper tract urothelial carcinoma
por: Su, Ruopeng, et al.
Publicado: (2023)

Prospective Clinical Trial of the Oncologic Outcomes and Safety of Extraperitoneal Laparoscopic Extended Retroperitoneal Lymph Node Dissection at Time of Nephroureterectomy for Upper Tract Urothelial Carcinoma
por: Huang, Jiwei, et al.
Publicado: (2022)

Prognostic value of preoperative plasma fibrinogen level and platelet-to-lymphocyte ratio (F-PLR) in patients with localized upper tract urothelial carcinoma
por: Huang, Jiwei, et al.
Publicado: (2016)

Preoperative serum pre-albumin as an independent prognostic indicator in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy
por: Huang, Jiwei, et al.
Publicado: (2016)

Influence of American Society of Anesthesiologists Score on Oncologic Outcomes in Patients With Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: A Large-Sample Study in Two Institutions
por: Yuan, Yichu, et al.
Publicado: (2021)

Body Composition Parameters May Be Prognostic Factors in Upper Urinary Tract Urothelial Carcinoma Treated by Radical Nephroureterectomy
por: Pan, Yulong, et al.
Publicado: (2021)

Editorial: Evidence and emerging option in diagnosis and management of upper tract urothelial carcinomas
por: Liu, Liangren, et al.
Publicado: (2022)

Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody
por: Huang, Jiwei, et al.
Publicado: (2021)

Effectiveness and safety of combined therapy versus monotherapy based on immune checkpoint inhibitors and/or targeted drugs as salvage treatment for advanced urothelial carcinoma: a systematic review and meta-analysis
por: Wei, Lichao, et al.
Publicado: (2021)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Nephroureterectomy increase 5 year survival in patients on dialysis with upper urinary tract urothelial carcinoma
por: Huang, Cih-En, et al.
Publicado: (2017)

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
por: Hsu, Fu-Shun, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

Microscopic hematuria predicts lower stage in patients with upper tract urothelial carcinoma
por: Qi, Nienie, et al.
Publicado: (2018)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer
por: Murakami, Kaoru, et al.
Publicado: (2021)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions
por: Thouvenin, Jonathan, et al.
Publicado: (2021)

Dual Targeting of Endoplasmic Reticulum by Redox-Deubiquitination Regulation for Cancer Therapy
por: Cai, Biao, et al.
Publicado: (2021)

The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
por: Houssiau, Hélène, et al.
Publicado: (2022)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Camrelizumab monotherapy leading to partial remission for relapsed upper tract urothelial carcinoma after radical nephroureterectomy: a case report
por: Ni, Kangxin, et al.
Publicado: (2021)

Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group
por: Lin, Chung-Yu, et al.
Publicado: (2022)

Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
por: Dörrie, Jan
Publicado: (2016)

Characterization of Molecular Heterogeneity Associated With Tumor Microenvironment in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy
por: Zhong, Weimin, et al.
Publicado: (2021)

CSF-1 Overexpression Predicts Poor Prognosis in Upper Tract Urothelial Carcinomas
por: Hsu, Wei-Chi, et al.
Publicado: (2019)

First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis
por: Lin, Chang-Ting, et al.
Publicado: (2022)

Analysis of prognostic oncogene filaggrin (FLG) wild-type subtype and its implications for immune checkpoint blockade therapy in bladder urothelial carcinoma
por: Chen, Liang, et al.
Publicado: (2022)

Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors
por: Ishiyama, Yudai, et al.
Publicado: (2019)

Current Advances in Immune Checkpoint Inhibition and Clinical Genomics in Upper Tract Urothelial Carcinoma: State of the Art
por: Califano, Gianluigi, et al.
Publicado: (2022)

Patient‐Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug Screening
por: Li, Zhichao, et al.
Publicado: (2021)

Oncogenic Roles of Polycomb Repressive Complex 2 in Bladder Cancer and Upper Tract Urothelial Carcinoma
por: Huang, Eric Yi-Hsiu, et al.
Publicado: (2022)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

Global Trade Pattern of Traditional Chinese Medicines and China's Trade Position
por: Xiang, Liyao, et al.
Publicado: (2022)

The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy
por: Tsai, Tsung-Han, et al.
Publicado: (2023)

Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma
por: Lin, Wei-Yu, et al.
Publicado: (2022)

Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer
por: Uchida, Hideaki, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies
por: Ouyang, Tao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b9maelq9vrqa3sm0qetjgu5bbs